If no other option help...
Key Market Indicator:
F&G: 63
25.547,95 NASDAQ · 49.390,00 DOW · 6.947,26 S&P · 4.596,86 Gold · 63,45 BRENT

One Community. One Spirit. N#1 Broker.
all asset classes · all possibilities

Switch View
© Globe Newswire
06.01.2026
ISIN: US19249H1032

Coherus Oncology Inc
CHRS

LISTED

NASDAQ
Coherus Management to Present at the 44th Annual J.P. Morgan Healthcare Conference
News Preview
REDWOOD CITY, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS) today announced that senior management will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 10:30 a.m. Pacific Time. The presentation and Q&A session will be accessible via webcast through a link posted o...
Themefolio
Profiler
Peergroup
© BusinessWire
06.01.2026
ISIN: US81663L2007

GeneDx Holdings Corp
WGS

LISTED

NASDAQ
GeneDx Appoints Dr. Linda Genen as Chief Medical Officer to Accelerate the Future of Genomic-First Care
News Preview
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights today announced Linda Genen, MD, MPH as Chief Medical Officer to further strengthen the company’s commitment to delivering earlier answers and better outcomes for families through genomic insights. This press release features multimedia. View the full r...
Themefolio
Profiler
Peergroup
© BusinessWire
06.01.2026
ISIN: US88023B1035

Tempus AI, Inc.
TEM

LISTED

NASDAQ
Tempus to Present at 44th Annual J.P. Morgan Healthcare Conference
News Preview
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, will participate in the 44th Annual J.P. Morgan Healthcare Conference, taking place January 12-15, 2026, in San Francisco, California. Tempus Founder and CEO Eric Lefkofsky will deliver a presentation, followed by a live Q&A session,...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar

USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© PR Newswire
06.01.2026
ISIN: JP3546800008

Terumo Corporation
45430

LISTED

XJPX
Terumo Launches SurTract™ Safety Syringe in the United States, Powered by Roncadelle Operations' SafeR® Passive Safety Technology
News Preview
- New, retractable safety hypodermic line offers enhanced safety, reliability and ease of use while minimizing patient discomfort* -SOMERSET, N.J., Jan. 6, 2026 /PRNewswire/ -- Terumo Medical Corporation, a wholly-owned subsidiary of Terumo Corporation, announced the US launch of its SurTract™ Safety Syringe, powered by SafeR® passive safety techn...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© PR Newswire
06.01.2026
ISIN: US04962H2094

Atossa Therapeutics, Inc.
ATOS

LISTED

NASDAQ
Atossa Therapeutics Receives FDA "Study May Proceed" Letter for (Z)-Endoxifen Investigational New Drug Application for Metastatic Breast Cancer
News Preview
SEATTLE, Jan. 6, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing innovative medicines for unmet medical needs, today announced that the U.S. Food and Drug Administration ("FDA") issued a "Study May Proceed" letter for the Company's study in metastatic breast cancer which was the...
Themefolio
Profiler
Peergroup
© PR Newswire
06.01.2026
ISIN: GB00BN455J50

Worldwide Healthcare Trust PLC
WWH

LISTED

LSE
Worldwide Healthcare Trust PLC - Net Asset Value(s)
News Preview
WORLDWIDE HEALTHCARE TRUST PLC LEI: 5493003YBCY4W1IMJU04 NET ASSET VALUE The estimated un-audited net asset val...
Themefolio
Profiler
Peergroup
© PR Newswire
06.01.2026
ISIN: US03763A2078

Astrana Health Inc
AMEH

LISTED

NASDAQ
Astrana Health, Inc. to Participate in Upcoming Investor Conference
News Preview
ALHAMBRA, Calif., Jan. 6, 2026 /PRNewswire/ -- Astrana Health, Inc. ("Astrana," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ: ASTH), a physician-centric, technology-enabled healthcare company empowering providers to deliver accessible, high-quality, and high-value care to all, today announced that leadership i...
Themefolio
Profiler
Peergroup
© BusinessWire
06.01.2026
ISIN: US1241551027

Butterfly Network Inc
BFLY

LISTED

NYSE
Butterfly Network to Extend its Proprietary 3D Imaging Capabilities to Butterfly Garden Developers
News Preview
Butterfly Network, Inc. (NYSE: BFLY) (“Butterfly”, “the company”), a digital health company transforming care with handheld, whole-body ultrasound and intuitive software, today announced plans to release its Beam Steering API for advanced third-party AI application and technology development within the company’s Butterfly Garden™ and Ultrasound-on...
Themefolio
Profiler
Peergroup
© PR Newswire
06.01.2026
ISIN: US4781601046

Johnson & Johnson
JNJ

LISTED

NYSE
Johnson & Johnson unveils new data showing nipocalimab is the first and only investigational FcRn blocker with potential to reduce systemic lupus erythematosus (SLE) activity in a Phase 2 study
News Preview
The JASMINE study met the primary endpoint and key secondary and exploratory endpoints, including those indicating the potential of nipocalimab for steroid sparingSLE is one of the most prevalent and debilitating autoantibody diseases, causing one's own immune system to mistakenly attack various tissues, which can lead to potentially life-threaten...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.01.2026
ISIN: US23954D1090

Day One Biopharmaceuticals Inc
DAWN

LISTED

NASDAQ
Day One Completes Acquisition of Mersana Therapeutics
News Preview
Day One Bio today announced the successful close of its acquisition of Mersana Therapeutics, Inc....
Themefolio
Profiler
Peergroup
© PR Newswire
06.01.2026
ISIN: US89357L4023

TransCode Therapeutics, Inc.
RNAZ

LISTED

NASDAQ
TransCode Therapeutics Announces Publication of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in Glioblastoma
News Preview
TTX-MC138 is delivered to glioblastoma tumors in murine models of the disease, following intravenous injectionTTX-MC138 demonstrated suppression of miR-10b target and extended survival in aggressive glioblastoma modelsStudy supports future clinical development of TTX-MC138 for patients with glioblastomaBOSTON, Jan. 6, 2026 /PRNewswire/ -- TransCod...
Themefolio
Profiler
Peergroup
© PR Newswire
06.01.2026
ISIN: US28414H1032

Elanco Animal Health Inc
ELAN

LISTED

NYSE
Elanco to Participate in the 44th Annual J.P. Morgan Healthcare Conference
News Preview
INDIANAPOLIS, Jan. 6, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026. Jeff Simmons, president and CEO, and Bob VanHimbergen, executive vice president and CFO, will represent the company and respond to questions from analysts at 3...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© PR Newswire
06.01.2026
ISIN: US28036F1057

Edgewise Therapeutics Inc
EWTX

LISTED

NASDAQ
Edgewise Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026
News Preview
BOULDER, Colo., Jan. 6, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that Kevin Koch, Ph.D., President and Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference....
Themefolio
Profiler
Peergroup
© PR Newswire
06.01.2026
ISIN: US2166485019

Cooper Companies Inc
COO

LISTED

NASDAQ
CooperVision to Launch MyDay® MiSight® 1 day Myopia Control Soft Contact Lenses
News Preview
New Lenses Combine Advanced Silicone Hydrogel Material with Proven ActivControl® Technology*1 to Slow the Worsening of Myopia in Children†2,3FAREHAM, England, Jan. 6, 2026 /PRNewswire/ -- CooperVision today announced the forthcoming launch of MyDay® MiSight® 1 day contact lenses in the UK and select European and surrounding markets, expanding its...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.01.2026
ISIN: US58468P2065

MediciNova Inc
MNOV

LISTED

NASDAQ
2026 New Year’s Greetings from the CEO
News Preview
LA JOLLA, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875) provides shareholders a corporate update in the following Letter to Stockholders from CEO Yuichi Iwaki, M.D., Ph.D....
Themefolio
Profiler
Peergroup
© Globe Newswire
06.01.2026
ISIN: US0287191029

American Oncology Network, Inc.
AONC

LISTED

OTC
Lone Star Oncology and American Oncology Network Welcome Dr. Derrick Nguyen
News Preview
American Oncology Network and Lone Star Oncology Welcome Dr. Derrick Nguyen...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.01.2026
ISIN: IL0011839383

Alpha Tau Medical Ltd
DRTS

LISTED

NASDAQ
Alpha Tau Reports New Positive Results in Two Upcoming Presentations at ASCO GI 2026 Symposium Showcasing Immune-Preservation and High Disease Control in Montreal Pancreatic Cancer Alpha DaRT® Study
News Preview
- Final results from first pancreatic cancer study in Montreal demonstrate 81% disease control rate, or 87% excluding the first two patients -...
Themefolio
Profiler
Peergroup
© Newsfile
06.01.2026
ISIN: CA08772P2026

BetterLife Pharma Inc.
BETR

LISTED

CSE
BetterLife Pharma to Participate in YAFO Capital Access Asia Partnering Forum During JPM Week in San Francisco
News Preview
Vancouver, British Columbia--(Newsfile Corp. - January 6, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), an emerging biopharmaceutical company focused on development of BETR-001, its proprietary non-hallucinogenic derivative of lysergic acid diethylamide ("LSD") for the treatmen...
Themefolio
Profiler
Peergroup
© BusinessWire
06.01.2026
ISIN: US53566P1093

Lineage Cell Therapeutics Inc.
LCTX

LISTED

TLV
Lineage Takes Delivery of Gene-edited Hypoimmune Cell Line Under Partnership With Factor Bioscience
News Preview
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf,” cell therapies for serious medical conditions, today announced the receipt of a novel, induced pluripotent stem cell (iPSC) line containing hypoimmunity edits, from Factor Bioscience Inc. (“Factor”...
Themefolio
Profiler
Peergroup
© BusinessWire
06.01.2026
ISIN: US45257U1088

Immunome Inc
IMNM

LISTED

NASDAQ
Immunome to Present at 44th Annual J.P. Morgan Healthcare Conference
News Preview
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunome management will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 10:30 a.m. PST. Interested parties can access a live audio webcast of...
Themefolio
Profiler
Peergroup
© BusinessWire
06.01.2026
ISIN: US8835561023

Thermo Fisher Scientific Inc
TMO

LISTED

NYSE
Thermo Fisher Scientific to Present at the J.P. Morgan 2026 Healthcare Conference
News Preview
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present at the J.P. Morgan 2026 Healthcare Conference on Tuesday, January 13, 2026, at 11:15 a.m. (ET). A live webcast of the presentation will be available in the Investors section o...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
06.01.2026
ISIN: US01989F2083

Allstar Health Brands, Inc.
ALST

LISTED

OTC
ALST Signs Non-Disclosure Agreement with Major Toronto University for Proposed Allstar Sports Centre Development
News Preview
TORONTO, ON / ACCESS Newswire / January 6, 2026 / ALST is pleased to announce the signing of a Non-Disclosure Agreement (NDA) with a large, internationally recognized university located in Toronto, Ontario, to explore the potential development of an Allstar Sports Centre on approximately 8 acres of land.The NDA establishes a confidential framework...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.01.2026
ISIN: US69012T2069

Outlook Therapeutics, Inc.
OTLK

LISTED

NASDAQ
Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and Business Development
News Preview
ISELIN, N.J., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced it has appointed Laura Cantrell as Vice President of Corporate Strategy and Business Development....
Themefolio
Profiler
Peergroup
© Globe Newswire
06.01.2026
ISIN: US1266381052

CVRx Inc
CVRX

LISTED

NASDAQ
CVRx Announces Implementation of New Category I CPT Codes for Barostim Therapy
News Preview
MINNEAPOLIS, Jan. 06, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, confirmed today that Category I Current Procedural Terminology (CPT) codes for baroref...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.01.2026
ISIN: US92346J1088

Vericel Corp
VCEL

LISTED

NASDAQ
Vericel to Present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026
News Preview
CAMBRIDGE, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the 44th Annual J.P. Morgan Healthcare Conference at 2:15 p.m. ET (11:15 a.m. PT) on Wednesday, January 14, 2026....
Themefolio
Profiler
Peergroup
© Globe Newswire
06.01.2026
ISIN: US59935P2092

Milestone Scientific Inc
MLSS

LISTED

XASE
Milestone Scientific Launches The Wand® Ambassador Program to Expand Peer Engagement and Accelerate Market Adoption in Dentistry
News Preview
Pilot launched with six registered dental professionals; program expected to scale to 250 ambassadors over 12 months Pilot launched with six registered dental professionals; program expected to scale to 250 ambassadors over 12 months...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.01.2026
ISIN: US53216B1044

LifeMD, Inc.
LFMD

LISTED

NASDAQ
LifeMD Announces Closing of $50 Million Revolving Credit Facility with Citizens Bank, N.A.
News Preview
NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care and pharmacy services, today announced the closing of a new senior secured revolving credit facility (“RCF”) with Citizens Bank, N.A. (“Citizens”). The facility has a maturity date of January 2, 2029 and provides for up to $50 milli...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.01.2026
ISIN: US31573L1052

FibroBiologics Inc.
FBLG

LISTED

NASDAQ
FibroBiologics to Present at 9th Annual BFC Global Healthcare Business Development and Investment Conference
News Preview
HOUSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced...
Themefolio
Profiler
Peergroup
© BusinessWire
06.01.2026
ISIN: US86627T1088

Summit Therapeutics Inc
SMMT

LISTED

NASDAQ
Summit Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
News Preview
Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it will participate in and present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, California, on Monday, January 12, 2026 at 9:45 AM PT. Robert W. Duggan, Chairman and Co-Chief Executive Officer, and Dr. Maky Zanganeh, President...
Themefolio
Profiler
Peergroup
© BusinessWire
06.01.2026
ISIN: US04280A1007

Arrowhead Pharmaceuticals Inc
ARWR

LISTED

NASDAQ
Arrowhead Pharmaceuticals Announces Interim Clinical Data on RNAi-based Obesity Candidates Showing Weight Loss in Obese Patients with Diabetes and Improved Measures of Body Composition
News Preview
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim results from two Phase 1/2a clinical trials of ARO-INHBE and ARO-ALK7, the company’s investigational RNA interference (RNAi) therapeutics being developed as potential treatments for obesity. Preliminary results with Arrowhead’s promising new approach to treating obesity and met...
Themefolio
Profiler
Peergroup
© BusinessWire
06.01.2026
ISIN: US98887Q1040

Zai Lab Limited
ZLAB

LISTED

NASDAQ
Zai Lab Announces National Medical Products Administration (NMPA) Approval of AUGTYRO™ (repotrectinib) for Patients with NTRK-Positive Solid Tumors
News Preview
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) has approved the supplemental New Drug Application (sNDA) for AUGTYRO™ (repotrectinib) for the treatment of adult patients with solid tumors that harbor a neurotrophic tyrosine receptor kinase (NTRK) gene fusion. The approval is...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.01.2026
ISIN: US19207A1088

Coeptis Therapeutics, Inc.
COEP

LISTED

OTC
Coeptis Therapeutics S-4 Declared Effective by SEC, Proxy Mailing Begins in Anticipation of the Merger Transaction with Z Squared
News Preview
~ Annual/Special Meeting of Shareholders to be Held on January 30, 2026 ~ ~ Annual/Special Meeting of Shareholders to be Held on January 30, 2026 ~...
Themefolio
Profiler
Peergroup
© BusinessWire
06.01.2026
ISIN: US4622221004

Ionis Pharmaceuticals Inc
IONS

LISTED

NASDAQ
Ionis to present at 44th Annual J.P. Morgan Healthcare Conference
News Preview
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Brett P. Monia, Ph.D., chief executive officer, will present a company overview at the 44th Annual J.P. Morgan Healthcare Conference at 8:15 a.m. PT on Tuesday, January 13, 2026. A live webcast of the presentation can be accessed on the Investors & Media section of the Ionis web...
Themefolio
Profiler
Peergroup
© PR Newswire
06.01.2026
ISIN: US00287Y1091

AbbVie Inc
ABBV

LISTED

EURONEXT
MAVIRET® receives Health Canada Approval for the Treatment of Acute Hepatitis C Virus
News Preview
MAVIRET is the first and only oral eight-week pan-genotypic treatment option approved for people with acute or chronic hepatitis C virus (HCV) in CanadaMAVIRET received approval through Health Canada's Priority Review process, based on data from the Phase 3 M20-350 Study establishing it to be a highly efficacious treatment for people with acute he...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.01.2026
ISIN: US85916J4094

Stereotaxis Inc
STXS

LISTED

XASE
Stereotaxis Receives FDA Approval for MAGiC Ablation Catheter
News Preview
ST. LOUIS, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it obtained U.S. Food and Drug Administration (FDA) approval for the MAGiC™ Magnetic Interventional Ablation Catheter....
Themefolio
Profiler
Peergroup
© BusinessWire
06.01.2026
ISIN: US92790C1045

Viridian Therapeutics Inc
VRDN

LISTED

NASDAQ
Viridian Therapeutics Prepares for Transformational 2026
News Preview
Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for serious and rare diseases, today announces the company’s key priorities and anticipated catalysts for 2026. “Following another year of strong execution across our portfolio, we enter 202...
Themefolio
Profiler
Peergroup
© PR Newswire
06.01.2026
ISIN: US3724463027

Genprex, Inc.
GNPX

LISTED

NASDAQ
Genprex Announces Positive Preliminary Preclinical Data from Study of GPX-002 in Type 2 Diabetic Animal Studies
News Preview
Preliminary Preclinical Data Demonstrates In Vivo Proof-of-Concept for Novel Diabetes Gene Therapy in Type 2 Diabetic Non-Human PrimatesGPX-002 Rejuvenated Exhausted Beta Cells and Normalized Glucose Levels in Type 2 Diabetic MiceAUSTIN, Texas, Jan. 6, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.01.2026
ISIN: US9032141049

Cogent Biosciences, Inc.
COGT

LISTED

NASDAQ
Cogent Biosciences Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference
News Preview
WALTHAM, Mass. and BOULDER, Colo., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that Andrew Robbins, President and Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Confere...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.01.2026
ISIN: US1569441009

CG Oncology, Inc.
CGON

LISTED

NASDAQ
CG Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference
News Preview
IRVINE, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that Arthur Kuan, Chairman & Chief Executive Officer, and Ambaw Bellete...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.01.2026
ISIN: BE0974461940

MDxHealth S.A.
MDXH

LISTED

NASDAQ
Mdxhealth and University of Oxford to validate GPS test in largest randomized trial of treatment effectiveness in patients with localized prostate cancer
News Preview
Mdxhealth and University of Oxford to validate GPS test in largest randomized trial of treatment effectiveness in patients with localized prostate cancer...
Themefolio
Profiler
Peergroup
© BusinessWire
06.01.2026
ISIN: IE00B56GVS15

Alkermes Plc
ALKS

LISTED

NASDAQ
Alixorexton Granted Breakthrough Therapy Designation by U.S. FDA for the Treatment of Narcolepsy Type 1
News Preview
Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to alixorexton for the treatment of narcolepsy type 1 (NT1), based on phase 1 and phase 2 clinical data, including positive results from Vibrance-1, a large (n=92) phase 2 study evaluating alixorexton in patient...
Themefolio
Profiler
Peergroup
© BusinessWire
06.01.2026
ISIN: US45784P1012

Insulet Corp
PODD

LISTED

NASDAQ
Insulet Redefines Diabetes at CES with "Liveable Technology" — A New Frontier in Human-Centered Connected Health
News Preview
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its debut at Consumer Electronics Show (CES) 2026, where the Company will showcase its vision for liveable technology through an immersive booth experience, expert panel session, an...
Themefolio
Profiler
Peergroup
© BusinessWire
06.01.2026
ISIN: IT0004147952

Newron Pharmaceuticals SpA
NWRN

LISTED

SIX
Newron Further Expands Intellectual Property Portfolio for Evenamide with New EU Composition of Matter Patent
News Preview
Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced that the European Patent Office (EPO) has issued the decision to grant an additional patent covering its lead developmen...
Themefolio
Profiler
Peergroup
© BusinessWire
06.01.2026
ISIN: US74587B1017

Pulse Biosciences Inc
PLSE

LISTED

NASDAQ
Pulse Biosciences Selected to Present Late-Breaking Data from the nPulse Cardiac Catheter Study at the AF Symposium
News Preview
Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced that late-breaking data from the nPulse Cardiac Catheter Ablation System first-in-human feasibility study in Europe has been accepted for presentation a...
Themefolio
Profiler
Peergroup
© PR Newswire
06.01.2026
ISIN: US14149Y1082

Cardinal Health Inc
CAH

LISTED

NYSE
Cardinal Health to Announce Second-Quarter Results for Fiscal Year 2026 on February 5
News Preview
DUBLIN, Ohio, Jan. 6, 2026 /PRNewswire/ -- Cardinal Health (NYSE: CAH) plans to release second-quarter financial results for its fiscal year 2026 on February 5, prior to the opening of trading on the New York Stock Exchange. The company will webcast a discussion of these results beginning at 8:30 a.m. Eastern....
Themefolio
Profiler
Peergroup
© Globe Newswire
06.01.2026
ISIN: KYG1281K1067

Silexion Therapeutics Corp
SLXN

LISTED

NASDAQ
Silexion Therapeutics Releases CEO Letter to Shareholders Highlighting 2025’s Significant Achievements and Outlining Upcoming Milestones for 2026
News Preview
SIL204 Demonstrated Significant Tumor Inhibition in Positive Pre Clinical Studies with Activity Across Pancreatic, Colorectal, and Lung Cancer Models...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.01.2026
ISIN: US0048901096

Acrivon Therapeutics Inc
ACRV

LISTED

NASDAQ
Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast
News Preview
Company to host conference call and webcast at 8:30 a.m. ET on Thursday, January 8, 2026 Company to host conference call and webcast at 8:30 a.m. ET on Thursday, January 8, 2026...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.01.2026
ISIN: US19243B1026

Cognition Therapeutics, Inc.
CGTX

LISTED

NASDAQ
Cognition Therapeutics Publishes Phase 2 Clinical Results Showing Zervimesine’s Potential to Slow the Progression of Dementia with Lewy Bodies
News Preview
- Zervimesine exhibited meaningful improvement in behavioral, functional, cognitive, and movement measures compared to placebo - - Zervimesine exhibited meaningful improvement in behavioral, functional, cognitive, and movement measures compared to placebo -...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.01.2026
ISIN: US7599161095

Repligen Corp
RGEN

LISTED

NASDAQ
Repligen Executive Chair Tony Hunt to Retire; Dr. Martin D. Madaus Elected Chair
News Preview
WALTHAM, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that the Board has elected Dr. Martin D. Madaus as Chair of the Board, effective March 13, 2026. As previously communicated1, Tony Hunt is retiring from his role as Executive...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.01.2026
ISIN: US09075A1088

Bioventus Inc
BVS

LISTED

NASDAQ
Bioventus to Present at the 44th Annual J.P. Morgan Healthcare Conference
News Preview
DURHAM, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Rob Claypoole, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 9:45 a.m. PT (12:45 p.m. ET)....
Themefolio
Profiler
Peergroup
© Globe Newswire
06.01.2026
ISIN: US0327973006

Anavex Life Sciences Corp
AVXL

LISTED

NASDAQ
Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program
News Preview
NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, an...
Themefolio
Profiler
Peergroup
© BusinessWire
06.01.2026
ISIN: US20451W1018

COMPASS Pathways plc
CMPS

LISTED

NASDAQ
Compass Pathways Establishes Strategic Collaboration with Radial to Innovate Patient Experience and Inform Potential Delivery Model of COMP360
News Preview
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it is entering into its seventh strategic collaboration, with Radial Health, Inc., a growing national network of interventional psychiatry practices leveraging technology and operations expertise to opt...
Themefolio
Profiler
Peergroup
© PR Newswire
06.01.2026
ISIN: SE0010323311

BioArctic AB
BIOA B

LISTED

STO
BLA for subcutaneous formulation of Leqembi® accepted in China
News Preview
STOCKHOLM, Jan. 6, 2026 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the Biologics License Application (BLA) for the subcutaneous formulation (subcutaneous autoinjector: SC-AI) of Leqembi (lecanemab) for treatment of early Alzheimer's disease has been accepted by the National Medical Products...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.01.2026
ISIN: US8162121045

Selecta Biosciences, Inc.
SELB

LISTED

NASDAQ
Cartesian Therapeutics Announces New Employment Inducement Grants
News Preview
FREDERICK, Md., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to two new employees. On January 2, 2026, the Company issued to these employees options to purchase...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.01.2026
ISIN: US09058V1035

BioCryst Pharmaceuticals Inc
BCRX

LISTED

NASDAQ
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
RESEARCH TRIANGLE PARK, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted one newly-hired employee restricted stock units (RSUs) covering an aggregate of 18,300 shares of BioCryst common stock. The RSUs were granted as of J...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.01.2026
ISIN: US6876041087

Oruka Therapeutics, Inc.
ORKA

LISTED

NASDAQ
Oruka Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
News Preview
MENLO PARK, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced that the Company will present at the 44th Annual J.P. Morga...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.01.2026
ISIN: US88688T1007

Tilray Brands, Inc.
TLRY

LISTED

TSX
Tilray Brands Expands Dry January Offerings with Zero-Proof Spirits, Non-Alcoholic Beers and Hemp-Derived THC Beverages
News Preview
NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY), a global lifestyle and consumer packaged goods company at the forefront of the beverage, cannabis and wellness industries, is redefining what it means to drink mindfully with a collection that blends craft, creativity, and functionality. From hemp-derived d...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.01.2026
ISIN: US81750R1023

Seres Therapeutics, Inc.
MCRB

LISTED

NASDAQ
Seres Therapeutics Announces Publications in Nature Medicine and Journal of Infectious Diseases Highlighting Vowst™ Mechanism of Action and Supporting Broader Live Biotherapeutic Strategy
News Preview
Data demonstrate clinical translation of VOWST mechanisms of action in both first and multiply recurrent CDI patients...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.01.2026
ISIN: US44975P1030

I-Mab
IMAB

LISTED

NASDAQ
NovaBridge Presents Positive Givastomig Dose Expansion Data from the Phase 1b Combination Study in Patients with 1L Metastatic Gastric Cancer
News Preview
ROCKVILLE, Md., Jan. 06, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovative medicines, today announced positive updated results from the Phase 1b combination study of givastomig, a Claudin 18.2 (CLDN18.2) x 4-1BB bispecifi...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.01.2026
ISIN: US09058V1035

BioCryst Pharmaceuticals Inc
BCRX

LISTED

NASDAQ
BioCryst to Present at 44th Annual J.P. Morgan Healthcare Conference
News Preview
RESEARCH TRIANGLE PARK, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 12, 2026, at 1:30 p.m. ET....
Themefolio
Profiler
Peergroup

More sector specific news

Your Press Release is missing or you want share news over GICS11? Drop us a line.

Gamechanger in online marketing · Innovation as a service · Upgrade your own internet presence.

© 2026 Select Sector SPDRs

* * *

More Sector related Investment Ideas
© 2026 WEBs Investments ETFs
About the newsfeed
#1
What types of information are provided on this portal - and what purpose does it serve?
The portal provides structured, stock market-relevant company information that is specifically assigned to a particular economic sector. The focus is on current announcements from official NewsWire sources, supplemented by company profiles, filter options by sector and sector-specific research aids. The aim is to offer an interested group of people a systematically structured research environment that improves their understanding of sector developments and corporate strategies.
#2
Why are companies categorized according to a certain system?
Financial markets consist of thousands of listed companies with very different business models. In order to create transparency and comparability, companies worldwide are assigned to standardized classifications. These classifications help investors to better analyze markets, identify sector-specific trends and make more targeted investment decisions.
#3
What classification standards exist for grouping companies?
There are various industry classifications that are used depending on the region or application. The best known include GICS (Global Industry Classification Standard), ICB (Industry Classification Benchmark), NAICS (North American Industry Classification System) and TRBC (Thomson Reuters Business Classification). Most institutional investors and ETFs worldwide use GICS or ICB as a benchmark.
#4
What classification standard is this financial information portal based on?
The portal uses the Global Industry Classification Standard (GICS), which was jointly developed by MSCI and S&P Dow Jones Indices. GICS is widely used in the institutional financial world and forms the basis for many global equity indices, ETFs and research systems.
#5
What exactly does GICS mean - and how is the system structured?
GICS stands for Global Industry Classification Standard. It is a hierarchical structure that divides listed companies worldwide into four levels: Sector, Industry Group, Industry Sector and Sub-Industry. In total, the system comprises 11 main sectors, over 60 industries and more than 150 sub-categories. It allows a consistent, internationally comparable analysis of economic activities.
#6
Why is GICS important in the financial world?
GICS offers a standardized language for investment decisions. It makes it possible to compare companies with similar business models - regardless of country, stock exchange or company size. Many investment funds, indices and research houses use GICS as a basis for portfolio construction, risk analysis or market screening. This means that it also makes sense for private investors to use this structure as a guide.
#7
Who decides which GICS sector a company is assigned to?
The allocation is made by the index providers MSCI and S&P Dow Jones on the basis of a company's main business segment. The decisive factor is the segment from which the company generates the majority of its sales or operating profit. Changes in the business model or strategic realignments can lead to a company being assigned to a different industry or even a different sector.
#8
What is meant by the GICS sector "Materials"?

The GICS "Materials" sector comprises companies that are active in the production, processing or refinement of raw materials. This includes industries such as chemicals, building materials, paper & forest products and the entire metallurgical and mining industry. The sector is highly cyclical and is particularly sensitive to economic fluctuations and changes in global demand.

#9
Which companies typically belong to the Materials sector?
Typical representatives are international groups from the areas of chemicals production (e.g. BASF), precious metal mining (e.g. Barrick Gold), building materials production (e.g. Heidelberg Materials) or industrial gases (e.g. Linde). The shares of these companies are often heavily dependent on commodity prices and play a central role in industrial value chains.
#10
Where does the company news on this page come from?
The news is based on verified and publicly available sources such as BusinessWire, GlobeNewswire, PR Newswire, EQS, Newsfile, ACCESSNewswire and other NewsWire services. These platforms are used by listed companies to publish mandatory ad hoc announcements, financial reports or strategic developments. All content is prepared in a structured manner and, if a corresponding categorization is possible, brought together in industry-specific clusters.
#11
How is the sector-specific mapping of messages carried out?
Categorization is based on structured metadata (e.g. ISIN, ticker, sector classification) and a combination of keyword analysis and GICS mapping. This ensures that all news is assigned to the correct sector and - if available - the correct sub-sector.
#12
Why is the materials sector particularly interesting for investors?
The Materials sector is closely linked to global industrial production and offers both cyclical growth opportunities and hedging opportunities against inflation and raw material shortages. In addition, many companies in this sector play a key role in future topics such as electromobility, the energy transition and sustainable building materials.
#13
What distinguishes this project from traditional financial information portals?
In contrast to generic portals, this project focuses exclusively and specifically on a particular sector. The advantage for interested investors: Sector-specific information, news, market movements and company profiles can be filtered and analyzed in a more targeted manner. This enables more in-depth research and greater relevance for thematic investment decisions.
#14
Are smaller companies also represented here or only large corporations?
The newsfeed takes into account both large caps and mid and small caps. As a clear mapping criterion is required in order to enable the most precise possible allocation to a cluster, the ISIN of the listed company is generally used for this purpose, provided that this can be made available or mapped via corresponding newsfeed parameters.
#15
How up-to-date are the displayed messages?
The content is updated regularly. The publication follows the publications of the information source, the NewsWire feeds of the underlying distributors. Incoming reports are automatically processed, classified and displayed on the page. Timestamps and source information ensure maximum transparency.
#16
Can I also filter the news by sub-sector?
Yes, this is a central feature of the site. Within a main sector, you can filter specifically for sub-sectors such as "Metals & Mining". For particularly popular industries or developments within a meta-sector, it is possible to deviate from standard clusters. Special categories with particular information value enable thematic analyses to be carried out even more precisely.
#17
Are there plans to process other metasectors in a similar way?
Yes, this financial information portal is part of an extensive project in which separate information portals are being created for all the main sectors. The aim is to provide investors with a systematic, sector-based research tool - regardless of index affiliation or provider perspective.
#18
Why do companies publish announcements via NewsWire services at all?
NewsWire services such as BusinessWire or PR Newswire fulfill a regulatory function: they enable companies to publish price-sensitive information publicly and without discrimination. In many countries, the use of such services is a prerequisite for fulfilling publication obligations under capital market law. They also enable companies to reach the media, analysts and investors in a targeted manner.
#19
Can private or inactive companies also appear in such notifications?
Generally not. The platform focuses exclusively on listed companies whose disclosures are based on regulatory requirements or corporate strategy measures. Although private or unlisted companies occasionally publish announcements, these are not systematically processed or classified here.
#20
What happens when a company changes its business model - does its sector classification also change?
Yes, as a rule - but not automatically. The responsible classification institutes (e.g. MSCI and S&P for GICS) regularly check the relevance and consistency of the classifications. If there is a significant change in a company's sales or profit profile, it may be reclassified to a different industry or even a different sector. This usually takes place after fixed review cycles or upon request.
#21
How is it ensured that a company is correctly categorized if it is active in several business areas?
The categorization is based on the dominant sales segment. If a company is active in several sectors but generates 70% of its turnover with chemical products, for example, it is assigned to the GICS sector "Materials" - even if it also has activities in the energy or transportation sector. In borderline cases, additional qualitative assessment criteria apply.
#22
Are there any legal risks in the further use of the displayed content?
The content comes from public sources, but is partially subject to copyright protection - particularly with regard to text structure and layout. The excerpts and links provided on this portal are made within the scope of permitted use (e.g. right to quote or editorial processing). However, commercial use by third parties is not permitted without the express permission of the original providers.
#23
Who can I contact if I have general questions or legal concerns?
A central contact point is available for general inquiries, information on company recordings, compliance issues or copyright-relevant aspects. In rare cases, for example in the case of erroneously published information or justified requests for deletion, a review and, if necessary, removal from the public feed can take place. Please only use the official contact option in the legal notice or at the bottom of the page.
#24
Is advertising or third-party content also displayed on the portal?
Yes, in defined areas the portal can display advertising content or product-specific information from third parties - for example on sector-related financial services, research offers or trading platforms. This content is clearly marked as advertising or partner information and is separate from the editorial or automatically processed company news.
#26
Can I give feedback on the platform or submit suggestions?
Absolutely - feedback is expressly welcome. The platform is an open information service that is continuously being developed. Comments on functionality, data quality, usability or thematic extensions help to optimize the service for the benefit of users. You can submit your suggestions informally via the contact page or special feedback forms.
#27
I am an information provider - can I cooperate with the portal?
Yes, the portal is open to content-related, technical or editorial cooperation, provided that this contributes to the quality, relevance or dissemination of the offering. If you offer content, interfaces or services that could be useful in the context of stock market-related information, we would be pleased to hear from you. The platform offers flexible integration options and a professional environment for quality-assured content.
#28
Can the platform technology also be used for other applications or partners?
Yes, the platform is based on a modular, scalable infrastructure that can be adapted to different information contexts and industry models. Technical components such as data aggregation, structuring logic, classification mechanisms and semantic filters can also be made available for external projects or individual applications on request. Please contact us for cooperation or license models.
#29
Can the underlying company data also be licensed or reused?
Structured access to selected master data of listed companies - such as GICS mapping, ISIN mapping, news feeds or metadata filters - is generally possible. The offer is aimed in particular at information service providers, research platforms or data-driven financial applications. Data can be provided via defined interfaces (e.g. API) or exportable formats, depending on the intended use and license framework.
#30
What forms of cooperation with external partners are conceivable?
Basically open. Possible forms of cooperation range from technical integrations and shared data models to content syndication or white label solutions. Partnerships with institutions that are looking for access to quality-assured data, dynamically structured news or sector-specific analyses - for example in the FinTech, media or research environment - are particularly interesting. We look forward to hearing from business development or product management departments.
#31
Why does this portal differ technically and conceptually from other information offerings?
Because no one from outside the industry is trying to understand the financial market here - but because the know-how comes from the heart of the financial world. The technical platform was developed by a team that combines in-depth market knowledge with innovative system design. The result: information architecture with real relevance, not shop window technology.
#32
What makes the technical solution particularly interesting for operators of their own financial portals?
In addition to high adaptability, the platform impresses with its modular structure and the consistent implementation of industry-specific logic - from GICS mapping to metadata filtering. For providers who operate their own information portals, sector-specific data structures, news feeds or visualizations can be quickly integrated on this basis - either as a white label, API module or embedded solution.
#33
Why can a collaboration go beyond traditional development services?
Because we don't just program, we think: The technological implementation is based on a deep understanding of market cycles, regulations, data formats and investor needs. Anyone who cooperates with this platform benefits from a sparring partner at eye level - both technically and professionally. This creates added value that goes far beyond pure IT expertise.
#34
Note on copyright and the processing of original content
The corporate news presented on this information portal is based on publicly accessible sources such as BusinessWire, GlobeNewswire, PR Newswire or comparable news services. The content is processed as part of an automated or editorially supported structuring process without changing, shortening or reinterpreting the content of the original information. This is so-called "as is" information, the form and content of which corresponds to the originally published announcement. The rights to the original texts remain unrestrictedly with the respective publishers or copyright holders. This portal merely assumes a structural categorization and allocation within the framework of a news-journalistic offer. Independent commercial reuse, systematic reproduction or other use of the content by third parties is only permitted within the framework of the statutory provisions or with the consent of the copyright holder.
About GICS Health
GICS Health is part of the GICS Eleven information portfolio, which focuses primarily on information from listed companies in the health sector. The sector classification serves as a guide to navigate quickly and conveniently through the latest industry-specific news. Individual peer group clusters complement the news offering.
About GICS Eleven

GICS Eleven (G11, GICS11) bundles topic-specific content and enables quick access to relevant information thanks to its gate function. The project is largely based on the Global Industry Classification Standard (GICS®), which was developed by MSCI and Standard & Poor's and enables a breakdown into sectors. GICS® consists of 11 sectors, 24 industry branches, 69 industries and 158 sub-industries.

GICS® is a registered trademark of MSCI Inc. and S&P Dow Jones Indices.

Member of 3R/RSQ Network
Digital Content
Network Alliance
Transparency - Reliability - Credibility
Information regarding Product Information
Sunday, 18.01.2026, Calendar Week 03, 18th day of the year, 347 days remaining until EoY.